BSI-507 / Biosion - LARVOL DELTA

BSI-507, a first-in-class bispecific antibody targeting PD1 and PVRIG for cancer immunotherapy (AACR 2023) - "BSI-507, an anti-PD1xanti-PVRIG bispecific antibody demonstrated comparable activity to the parental anti-PD1 antibody regarding PD1 binding and PD1/PDL1 blocking. It also exhibited comparable activity to the parental anti-PVRIG antibody in PVRIG binding and PVRIG/PVRL2 blocking. Based on cell-based reporter assays, BSI-507 was able to reverse either PD1 or PVRIG mediated T-cell suppression and exhibited comparable potency to the parental antibodies."

Oncology • CD4 • CD8

Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023 (PRNewswire) - "Biosion USA...announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bispecific antibody, at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 14 to 19, 2023."

Preclinical • Oncology